Prognosis of 2800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital

Acta Obstetricia et Gynecologica Scandinavica

Volumn 77, Issue 7, 1998, Pages 777-781

  Bjørge, Tone ^a,b   Engeland, Anders ^c   Sundfør, Kolbein ^a   Tropé, Claes G ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b CANCER REGISTRY OF NORWAY   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Epithelial ovarian cancer; Prognosis

Indexed keywords

ARTICLE; CANCER STAGING; CANCER SURVIVAL; EPITHELIUM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NORWAY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; STATISTICAL MODEL; ADOLESCENT; ADULT; AGED; CARCINOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARY TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NORWAY; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0031874096     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1080/j.1600-0412.1998.770714.x     Document Type: Article

References (19)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594-606.
2. Hanai A. Trends and differentials in ovarian cancer: incidence, mortality and survival experience. APMIS Suppl 1990; 12: 1-20.
3. Bjørge T, Engeland A, Hansen S, Tropé CG. Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954-93. Int J Cancer 1997; 71: 780-6.
4. Pettersson F. Annual Report on the results of treatment in gynecological cancer. Stockholm: International Federation of Gynecology and Obstetrics, 1994.
5. Bjørge T, Engeland A, Hansen S, Tropé CG. Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993. Int J Cancer 1998; 75: 663-70.
6. Kristensen GB, Tropé C. Epithelial ovarian carcinoma. Lancet 1997; 349: 113-17.
7. Pettersson F. Annual report on the results of treatment in gynecological cancer. Stockholm: International Federation of Gynecology and Obstetrics, 1988.
8. Serow SF, Scully RE, Sobin LH. Histologic typing of ovarian tumors. Geneva: World Health Organization, 1973.
9. Cox DR, Oakes D. Analysis of Survival Data. London: Chapman & Hall Ltd, 1984.
10. SPSS Inc. SPSS for Windows. Release 6.1.2. Chicago: SPSS Inc., 1995.
11. Balvert-Locht HR, Coebergh JW, Hop WC, Brolmann HA, Crommelin M, van Wijck DJ et al. Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study. Gynecol Oncol 1991; 42: 3-8.
12. Levi F, Franceschi S, La Vecchia C, Ruzicka J, Gloor E, Randimbison L. Epidemiologic pathology of ovarian cancer from the Vaud Cancer Registry, Switzerland. Ann Oncol 1993; 4: 289-94.
13. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985; 312: 1604-8.
14. Griffiths CTH. Surgical resection of tumor bulk in the primary treatment of ovarian cancer. Natl Cancer Inst Monogr 1975; 42: 101-4.
15. Allen DG, Heintz AP, Touw FW. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 1995; 16: 349-56.
16. Young RC, Chabner BA, Hubbard SP. Fisher RI, Bender RA, Anderson T et al. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 1978; 299: 1261-6.
17. Young RC, Von Hoff DD, Gormley P, Makuch R, Cassidy J, Howser D et al. Cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. Cancer Treat Rep 1979; 63: 1539-44.
18. Barker GJ, Wiltshaw E. Use of high dose cis-dichlorodiammineplatinum (II) (NSC-119875) following failure on previous chemotherapy for advanced carcinoma of the ovary. Br J Obstet Gynaecol 1981; 88: 1192-6.
19. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.